ARTCLINE Secures €5 Million for Clinical Trial Advancement

ARTCLINE GmbH, headquartered in Rostock, Germany, has successfully closed a €5 million financing round through a convertible loan. This financial boost will enable the completion and assessment of the ongoing ReActIF-ICE clinical trial. The study is pivotal for validating the ARTICE® therapy, aimed at treating immune dysfunction in septic shock patients.

This recent funding round received substantial backing from both existing and new investors, underscoring strong market confidence in ARTCLINE's innovative approach. The ReActIF-ICE study, expected to conclude in early 2026, addresses significant unmet medical needs within a complex medical field deeply impacting global health systems.

On September 29, 2025, ARTCLINE plans to host a webinar providing insights into the ARTICE® therapy, its current trial progress, and the company's future strategies. This session will offer valuable information for investors and media, highlighting ARTCLINE’s strategic outlook and treatment advancements.